How to monitor treatment
By measuring the expression of specific genes in CD3+ cells, the method ensures naltrexone is administered at effective levels, optimizing treatment efficacy and minimizing side effects by enhancing immune system priming and anti-cancer drug activity.
Patent Information
- Application Number
- JP2021552878
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-06
- Filing Date
- 2020-03-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-03-06
AI Technical Summary
Current methods lack a straightforward way to monitor whether naltrexone is administered at effective levels to further reduce cancer growth caused by chemotherapeutic agents, and there is a need for monitoring treatment effects on individual patients to optimize therapeutic doses and minimize side effects.
A method is developed to monitor treatment by measuring the expression profile of specific genes in CD3+ cells, such as S100 calcium binding protein A6 and RAS protein activator-like 3, to determine if naltrexone or its metabolites or analogues are administered at effective low doses, thereby enhancing the immune system's priming effect.
This method allows for adjusting the dosage of naltrexone to maximize therapeutic efficacy while minimizing side effects by ensuring the drug is administered at the appropriate low dose, boosting CD3+ cell activity and enhancing the cytotoxic or cytostatic activity of anti-cancer drugs.
Smart Images

Figure 0007584431000004 
Figure 0007584431000001 
Figure 0007584431000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for monitoring the treatment of a subject by monitoring the expression profile of specific genes. [Background technology]
[0002] The success of many cancer treatments is based on the co-administration of an active cancer-targeting compound with an adjuvant-type molecule. Although having no independent therapeutic utility, the adjuvant serves to prime the subject's immune system so that the active cancer-targeting compound can achieve its maximum therapeutic effect.
[0003] Adjuvants typically modulate the patient's immune response and are therefore most often used in combination with biologics such as cancer vaccines and humanized antibody drugs. Adjuvants act by strengthening the patient's immune system and increasing antibody production in response to a challenge with a cancer vaccine, or by suppressing or reducing the patient's immunogenicity to foreign antibody drugs. Thus, adjuvants play an important role in ensuring the success of cancer immunotherapy.
[0004] Adjuvants are often used in combination with more traditional cancer treatments, such as radiation therapy or chemotherapy, resulting in a synergistic treatment where the presence of the adjuvant significantly increases the efficacy of the treatment, allowing for the use of less traditional cancer treatment, which is beneficial since many cancer treatments have negative side effects when administered in high doses.
[0005] With so many different factors that affect how a treatment will affect the body, such as a patient's age, sex, height, and weight, as well as environmental factors, it can be difficult to know if therapeutic agents and adjuvants are being administered at effective levels. Additionally, traditional cancer treatments often result in patients experiencing negative side effects, which can be exacerbated by suboptimal doses, which may vary from patient to patient.
[0006] In view of the above, there is a need to develop new treatment regimens that allow the effect of the treatment on an individual patient to be monitored, so that the patient receives an optimal therapeutic dose. If monitoring reveals that the optimal therapeutic dose is not being administered, the dosage of the therapeutic agent can be altered accordingly, so that the treatment is as effective as possible while minimizing the negative side effects of the treatment. Summary of the Invention
[0007] It is known that co-administration of naltrexone with a chemotherapy agent reduces cancer cell proliferation compared to administration of the chemotherapy agent alone, however, there is currently no simple method to monitor whether naltrexone is being administered at a level effective to further reduce the proliferation of cancer cells caused by the chemotherapy agent.
[0008] The inventors have previously reported that low dose naltrexone provides therapeutic advantages over previously used high dose regimens. The inventors have now discovered that treatment with low doses of an active agent that is naltrexone or a metabolite or analog thereof, when administered at appropriate levels, increases expression of the genes listed in Table 1 and decreases expression of the genes listed in Table 2 in CD3+ cells of a subject. Furthermore, the inventors have found that the expression levels of each of the above genes increase CD3+ cell activity. We have found that administration of high doses of naltrexone, however, has the opposite effect or no effect at all on the expression of these genes in CD3+ cells and therefore on the activity of CD3+ cells. Thus, by measuring and monitoring the expression levels of these genes, it is possible to determine whether the active agent is being administered at a low and effective level.
[0009] In a first aspect of the invention, there is provided a method for monitoring treatment of a subject undergoing therapy with an active agent that is naltrexone or a metabolite or analog thereof, comprising: measuring in a CD3+ cell sample obtained from the subject receiving the treatment a gene expression profile of any of the genes listed in a) or b) below: a) i. S100 calcium-binding protein A6 (mRNA); ii. RAS protein activator-like 3 (mRNA); iii. mitogen-activated protein kinase kinase kinase kinase 1 (mRNA); iv. tyrosine 3-monooxygenase / tryptophan 5-monooxygenase (mRNA); v. DR1-associated protein 1 (negative cofactor α2) (mRNA); vi. castor zinc finger 1, transcript variant 2 (mRNA); vii. Aldehyde dehydrogenase 4 family, member A1 (mRNA); viii. phenylalanine hydroxylase (mRNA); ix. myosin, light chain polypeptide kinase, transcript variant 5 (mRNA); x. Eukaryotic translation initiation factor 4B (mRNA); xi. Olfactory receptor, family 10, subfamily A, member 6 (mRNA); xii. Ezrin, transcript variant 1 (mRNA); xiii. actin, β (mRNA); xiv. PRP8 precursor RNA processing factor 8 (S. cerevisiae) homolog (mRNA); xv. integrin, β2 (complement component 3 receptors 3 and 4) (mRNA); xvi. Hippocalcin-like 1, transcript variant 2 (mRNA); xvii. SPARC / osteonectin, cwcv and Kazal-like domain proteoglycan 2 (mRNA); xviii. poliovirus receptor-related 2 (herpesvirus entry mediator B) (mRNA); xix. nucleobindin 1 (mRNA); or b) i. WD repeat domain 75 (mRNA); ii. baculovirus IAP repeat-containing 3, transcript variant (mRNA); iii. CDKN2A interacting proteins (mRNA); iv. dynein, light chain, LC8-type 2 (mRNA); v. Eukaryotic translation initiation factor 2, subunit 3 gamma (mRNA); vi. ArfGAP (mRNA) with SH3 domain, ankyrin repeats, and PH domain 1; vii. potassium channel tetramerization domain-containing 6 (mRNA); viii. Proteasome (prosome, macropein) activator subunit 2 (mRNA); ix. Mortality factor 4-like 1, transcript variant 2 (mRNA); x. Metal-regulated transcription factor 1 (mRNA); xi. Peroxisomal D3, D2-enoyl-CoA isomerase, transcript (mR NA); xii. programmed cell death 4 (proliferative transformation inhibitor) (mRNA); xiii. histone cluster 1, H4c (mRNA); xiv. BCL2-associated transcription factor 1, transcript variant (mRNA); xv. Eukaryotic translation initiation factor 3, subunit E (mRNA); xvi. LSM5 (S.cerevisiae) homolog, U6 nuclear small RNA binding (mRNA); xvii. H3 histone, family 3A (mRNA); xviii. Eukaryotic translation initiation factor 3, subunit M (mRNA); xix. CDC42 small molecule effector 2, transcript variant 2 (mRNA); If the expression of any of the genes in a) above is increased compared to a control, or if the expression of any of the genes listed in b) above is decreased compared to a control, the active agent is administered at an effective level. A method is provided.
[0010] The invention will be described with reference to the accompanying drawings. [Brief description of the drawings]
[0011] [Figure 1] 4 shows the results of Example 2; CD69 expression of PBMCs cultured with LDN, NTX, or DMSO. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention is based on the discovery that the active agent naltrexone or its metabolites or analogs, when administered at low and effective levels, increases the expression of the genes listed in Table 1 and decreases the expression of the genes listed in Table 2 in the CD3+ cells of a subject. This is exemplified by the compound naltrexone. That is, by measuring the expression levels of these genes in the CD3+ cells of a subject while undergoing treatment with naltrexone or its metabolites or analogs, a physician can monitor whether the agent is administered at the desired low and effective levels. Thus, the inventors have invented an in vitro method of monitoring treatment by measuring the expression levels of the genes listed in Table 1 or Table 2, which allows the amount of the active agent naltrexone or its metabolites or analogs administered to be modified to maximize efficacy and safety.
[0013] [Table 1]
[0014] [Table 2]
[0015] The present inventors have discovered that low-dose naltrexone (LDN) has a beneficial "priming" effect on the immune system, i.e., LDN is used to prime cells of the immune system prior to treatment with additional drugs / treatment options.
[0016] In a previous application, the inventors showed that priming with LDN as part of a first treatment phase before administration of additional drugs results in greater cell death than without a priming LDN phase or continuous LDN administration. However, there is currently no convenient method for determining whether an adequate amount of LDN has been administered and therefore whether a priming effect is present.
[0017] When administered to a subject undergoing treatment, an active agent such as naltrexone or a metabolite or analog thereof enhances the cytotoxicity and cytostatic activity of the anticancer agent being used to treat the subject. Without wishing to be bound by theory, an increase in the expression level of the genes in Table 1 or a decrease in the expression level of the genes in Table 2 indicates that the CD3+ cells are responding to the action of low doses of the active agent naltrexone or a metabolite or analog thereof and have been primed to have increased CD3+ activity. CD3+ cells are immune cells that play a key role in fighting disease in the body. Activation of CD3+ cells increases the proliferation of T cells, which are important in the body's defense against disease, thus effectively boosting the immune system. Furthermore, increased activity of these cells increases the overall cytotoxicity and subsequently the cytotoxicity of treatment regimens that include administration of additional therapeutic agents. Thus, the genes of Tables 1 and 2 are useful markers to identify whether the amount of active agent being administered is at a desired low and effective level that enhances the cytotoxic and cytostatic activity of an additional therapeutic agent that is subsequently administered when the active agent is at an effective level.
[0018] In some embodiments, the active agent is provided in an amount sufficient to increase the expression of any gene listed in Table 1 in CD3+ cells above the normal basal level expected in the subject. For example, the active agent may be administered in an amount sufficient to increase the expression level of any gene listed in Table 1 by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, 70%, at least 80%, at least 90%, or at least 100% compared to the normal basal level expected in the subject. In some embodiments, the active agent is provided in an amount sufficient to decrease the expression of any gene listed in Table 2 below the normal basal level expected in the subject. For example, the active agent is administered in an amount sufficient to decrease the expression level of any gene listed in Table 2 by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% compared to the normal basal level expected in the subject. The "normal" basal level of each gene may be determined by measuring the expression level of each gene in CD3+ cells of a sample obtained from the subject prior to administration of the active agent.
[0019] The expression level of the above genes can be measured in cell populations using any number of analytical methods available to those skilled in the art, including but not limited to quantitative polymerase chain reaction (PCR); real-time PCR; Northern blotting, DNA microarray, or sequencing.One example of such a commercially available platform is the Illumina platform with a chip for whole human genome testing.The increase or decrease in the expression level of a gene can be determined by comparing the expression level of the gene before and after administration of the active substance naltrexone, or its metabolite or analogue.
[0020] In an embodiment, the biological sample obtained from a subject used in the above method is blood, plasma, serum, lymph, tissue, or cells from a tissue sample, preferably a blood sample. Conventional techniques for obtaining any of the above biological samples from a subject are well known to those skilled in the art. The ability to use blood samples provides a convenient and simple platform for measuring gene expression and determining whether immune system priming has occurred.
[0021] The "standard" values used in the above methods can be the expression levels of the genes in Table 1 or Table 2 determined from biological samples obtained from healthy subjects. As used herein, a "healthy subject" refers to a subject not suffering from cancer or a central nervous system (CNS) disorder. The standard value may be determined by measuring the expression level of the genes of Table 1 or Table 2 in a sample obtained from a healthy individual when carrying out the method of the invention. Alternatively, the standard value may be a predetermined value from a prior measurement of the expression level of the genes of Table 1 or Table 2 in a comparable sample obtained from a healthy individual. When monitoring the treatment of the active agent that increases or decreases the expression of the genes of Table 1 or Table 2, the standard value may be obtained from a healthy individual, or the standard value may be the expression level of the genes of Table 1 or Table 2 measured in a sample previously obtained from the subject, i.e. the standard value may be the expression level of the genes of Table 1 or Table 2 in a sample obtained from the subject before administration of the active agent.
[0022] By comparing the genes of Table 1 or Table 2 of the subject with the standard, it is determined whether the amount of the active agent being administered is at a desired low dose and effective level. If the expression of the genes of Table 1 is increased compared to the standard, or the expression of the genes of Table 2 is decreased compared to the standard, the active agent is administered at a desired low dose and effective level. Conversely, if the expression of the genes of Table 1 is decreased compared to the standard or at the same level, or the expression of the genes of Table 2 is increased compared to the standard or at the same level, the active agent is not administered at a desired low dose and effective level. Thus, the amount of the active agent administered in the treatment regime can be adjusted accordingly, i.e., the amount of the active agent administered is reduced if it is administered at too high a dose and not at an effective level.
[0023] Preferably, expression of the genes of Table 1 or Table 2 is measured at least 24 hours after administration of the active agent, more preferably at least 48 hours after administration of the active agent.
[0024] The gene expression profile of any of the genes in Table 1 and Table 2 may be measured and compared with its standard value. However, the more genes that are measured and compared with the standard value, the more confident the person skilled in the art can be in the conclusion to determine whether the active substance is administered at an effective level. Thus, in some embodiments, the gene expression profile of two or more genes is determined, and suitably the gene expression profile of three or more genes, preferably four or more genes, more preferably five or more genes is determined.
[0025] In some embodiments, the gene expression profile of one or more, such as two or more, suitably three or more, preferably four or more, more preferably all five of the S100A6, RASAL3, MAP4K1, YWHAZ, and DRAP1 genes in Table 1 is determined, and / or the gene expression profile of one or more, such as two or more, suitably three or more, preferably four or more, more preferably all five of the WDR75, BIRC3, CDKN2AIP, DYNLL2, and EIF253 genes in Table 2 is determined. In a particular embodiment, the gene expression profile of all of the genes in Table 1 is determined, and / or the gene expression profile of all of the genes in Table 2 is determined.
[0026] The active agent is preferably administered at a low dose, i.e., in an amount effective to increase the plasma concentration of the active agent to at least 0.34 ng / ml, or at least 3.4 ng / ml, or at least 34 ng / ml, or at least 340 ng / ml. In one embodiment, the active agent is administered in an amount effective to increase the plasma concentration of the active agent to within the range of 0.3 ng / ml to 3,400 ng / ml, preferably within the range of 34 ng / ml to 3,400 ng / ml, more preferably within the range of 340 ng / ml to 3,400 ng / ml. An amount effective to achieve such an effect can be determined using any number of conventional techniques known to one of skill in the art. For example, one of skill in the art can perform mass spectrometry on a plasma sample obtained from a subject to determine the increase in concentration of the active agent in the sample after administration of an amount of the active agent. An effective amount is the amount determined to cause the desired increase in plasma concentration.
[0027] In one embodiment, the low dose, i.e., the effective amount of the active substance used in the treatment method, may be from about 0.01 mg to a maximum of 10 mg, preferably about 0.1 mg to about 8 mg, most preferably about 1 to about 6 mg of the active substance; for example, about 0.01 mg, about 0.05 mg, about 0.1 mg, about 0.3 mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 5 mg, about 10 mg of the active substance is used per day. In one embodiment, the effective amount of the active substance used per day is 4.5 mg or less, for example, 2 mg to 4.5 mg or 3 mg to 4.5 mg, preferably 3 mg to 4 mg.
[0028] As used herein, the terms "treating" and "treatment" and "to treat" and "therapy" refer to both 1) therapeutic measures that cure, slow the progression of, and / or halt a diagnosed pathological condition or disorder, and 2) prophylactic or preventative measures that prevent and / or delay the onset of the targeted pathological condition or disorder. That is, those in need of treatment include those already with the disorder; those susceptible to having the disorder; and those in whom the disorder is to be prevented.
[0029] As used herein, "naltrexone" refers to morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-(5α), as well as its pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs.The use of naloxone, a structural analogue of naltrexone, is also within the scope of the present invention and is encompassed by the term "analog" as used in the specification and claims.Methylnaltrexone is also contemplated as an analogue suitable for use in all aspects of the present invention.
[0030] 6-β-naltrexol is the main active metabolite of naltrexone and is included in the term "metabolite" used in the specification and claims. As used herein, "6-β-naltrexol" refers to 17-(cyclopropylmethyl)-4,5-epoxymorphinan-3,6β,14-triol, as well as its pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs. The term 6-β-naltrexol also includes its functionally equivalent analogs and metabolites that retain functional equivalence with respect to the novel uses of 6-β-naltrexol in each embodiment of the present invention. The preferred form of naltrexone or its metabolites or analogs is the hydrochloride form.
[0031] As used herein, "cytotoxicity" refers to the property of an agent to be toxic to cells. Cytotoxicity may therefore also refer to the ability of an agent to induce cell death upon contact with a cell. The cytotoxic mechanism leading to cell death may be by necrosis or programmed cell death (apoptosis). Cytotoxicity may be measured in a cell population using any number of cell viability assays or may be measured using antibodies specific for protein factors that are activated upon the initiation of apoptosis.
[0032] As used herein, "cytostasis" refers to the cessation of cell growth and proliferation. Cytostatic agents therefore refer to agents that inhibit proliferation or growth of cells, possibly without causing cytotoxicity. Agents that cause cytostasis can be determined by measuring the DNA content of individual cells in a cell population. A proliferating cell population will contain subpopulations of cells with different levels of DNA content. The DNA content in a cell will depend on the stage of the cell cycle in which the cell is located. If an agent causes cytostasis, the balance of cell populations in each stage of the cell cycle will be abnormal. For example, if cytostasis occurs in the S or G2 phase, an abnormal number of cells will contain twice the DNA content normally found in somatic cells. Conversely, if cytostasis occurs in the G0 or G1 phase, an abnormal number of cells will contain the amount of DNA normally found in somatic cells.
[0033] As used herein, the term "subject" refers to any animal (e.g., mammal), including, but not limited to, humans, non-human primates, dogs, cats, rodents, etc. Generally, the terms "subject" and "patient" are used interchangeably herein to refer to a human subject.
[0034] The subject may be undergoing treatment for several disorders, and LDN may be beneficial in the use of a series of treatments targeting different diseases, since the priming effect of LDN boosts the immune system. One such example is a patient who is immunocompromised by the disease itself (e.g., HIV / AIDS) or by the treatment associated with the disease (e.g., chemotherapy during cancer treatment). "Immunocompromised" or "immunocompromised" is a state in which the immune system is weakened or impaired, reducing the ability to fight infection. The treatment is preferably intended as or as part of a regimen for treating cancer, preferably breast cancer, lung cancer, melanoma, colon cancer, or glioma.
[0035] As used herein, the term "HIV" refers to the "human immunodeficiency virus," which is a virus that damages cells of the immune system, weakening its ability to fight common infections and diseases. "AIDS" refers to the "acquired immune deficiency syndrome," and describes a number of potentially life-threatening infections and illnesses that occur when the immune system is severely damaged by the HIV virus.
[0036] Typically, HIV is treated with antiretroviral drugs. Thus, after priming with LDN, antiretroviral therapy may be administered. Antiretroviral therapy is usually formulated with three different drug molecules. For example, nucleoside reverse transcriptase inhibitors (abacavir (Ziagen), emtricitabine (Emtriva), lamivudine (Lamivudine RBX, Zefix, Zetlam), etc.), non-nucleoside reverse transcriptase inhibitors (delavirdine (Rescriptor), doravirine (Pifeltro), efavirenz (Sustiva), etc.), protease inhibitors (atazanavir (Reyataz), darunavir (Prezista), fosamprenavir (Lexiva, Telzir), etc.), entry inhibitors (enfuvirtide (Fuzeon), maraviroc (Selzentry), etc.), and integrase inhibitors (dolutegravir (Tivicay), elvitegra (Vitekta), raltegravir (Isentress), etc.).
[0037] As used herein, the term "cancer" refers to any tissue mass resulting from excessive cell growth, proliferation, and / or survival, benign (non-cancerous) or malignant (cancerous), including precancerous lesions. As used herein, the term "cancer cell" refers to a cell line derived from a cancer or an immortalized cell line. Refers to...
[0038] Typically, cancer treatment includes one or more of chemotherapy, radiation therapy, hormone therapy, or immunotherapy. Thus, after priming with LDN, cancer treatment may be administered. As used herein, "chemotherapy", "chemotherapeutic agent", "radiotherapy", "hormonal therapy", and "immunotherapy" have their usual meaning in the art. The term "anticancer agent" is used synonymously with "chemotherapeutic agent". Multiple known treatments may be used by using combination therapy.
[0039] In one embodiment, the chemotherapy comprises administering an anti-cancer agent selected from the group consisting of a PI3-kinase inhibitor, an AKT inhibitor, a taxane, an antimetabolite, an alkylating agent, a cell cycle inhibitor, a topoisomerase inhibitor, and a cytotoxic antibody.
[0040] When the chemotherapeutic agent is a PI3-kinase inhibitor, suitable examples include, but are not limited to, wortmannin, LY294002, demethoxyviridin, IC87114, NVP-BEZ235, BAY80-6946, BKM120, GDC-0941, GDC-9080; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0041] When the anti-cancer agent is an AKT inhibitor, suitable examples include, but are not limited to, MK-2206, GSK690693, perifosine, PHT-427, AT7867, honokiol, PF-04691502; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0042] When the anti-cancer drug is a taxane, suitable examples include, but are not limited to, paclitaxel and docetaxel; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0043] When the anticancer agent is an antimetabolite, suitable examples include, but are not limited to, methotrexate, 5-fluorouracil, capecitabin, cytosine arabinoside (cytarabine), gemcitabine, 6-thioguanin, pentostatin, azathioprin, 6-mercaptopurin, fludarabine, and cladribine; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0044] When the anticancer agent is an alkylating agent, suitable examples include, but are not limited to, mechlorethamine, cyclophosphamide, ifosfamide, trofosfamide, melphalan (L-sarcolysin), chlorambucil, hexamethylmelamine, thiotepa, busulfan, carmustine (BCNU), streptozotocin, dacarbazine (DTIC; dimethyltriazenoimidazol ecarboxamide), temozolomide, and oxaliplatin; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0045] When the anticancer drug is a cell cycle inhibitor, suitable examples include epothilones. lone, Vincristine, Vinblastine, UCN-01, 17AAG, XL844, CHIR-124, PF-00477736, CEP-3891, Flavopiridol, Berberine, P276-00, Terameprocol, Isoflavone Examples of suitable agonists include, but are not limited to, daidzein, BI2536, BI6727, GSK461364, Cyclapolin, ON-01910, NMS-P937, TAK-960, Ispinesib, Monastrol, AZD4877, LY2523355, ARRY-520, MK-0731, SB743921, GSK923295, Lonafarnib, proTAME, Bortezomib, MLN9708, ONX0912, CEP-18770; and combinations thereof; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above. Particularly suitable examples of cell cycle inhibitors include, but are not limited to, Hesperadin, ZM447439, VX-680, MLN-8054, PHA-739358, AT-9283, AZD1152, MLN8237, ENMD2076, SU6668; and combinations thereof; and other Aurora kinase inhibitors; and pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs of any of the above.
[0046] Checkpoint inhibitors are a form of cancer immunotherapy with currently approved inhibitors that target CTLA4, PD-1, and PD-L1 molecules.
[0047] In another embodiment, the treatment may include administering to the subject Vitamin D. Vitamin D and the active agent may be administered in parallel or simultaneously, sequentially or separately, preferably simultaneously.
[0048] As used herein, "vitamin D" refers to vitamin D and any intermediate or product of the metabolic pathway of vitamin D that results in a metabolite that can boost the cytostatic effect of the active agent. Metabolites may refer to vitamin D precursors, which can be incorporated into the natural vitamin D synthesis pathway in a subject to carry out the treatment of the present invention. Alternatively, metabolites may refer to molecules resulting from anabolic or catabolic processes that utilize vitamin D. Non-limiting examples of vitamin D metabolites include ergocalciferol, cholecalciferol, calcidiol, and calcitriol, 1a-hydroxycholecalciferol, 25-hydroxycholecalciferol, 1a,25-hydroxycholecalciferol, and 24,25-hydroxycholecalciferol. An "active" metabolite is a metabolite that can be used in the context of the present invention. Dosage regimes of vitamin D or its active metabolites are well known to those skilled in the art. The term vitamin D also encompasses pharma-ceutically acceptable salts of any of the above. A particularly suitable metabolite of vitamin D for use in the present invention is calcitriol.
[0049] As used herein, the terms "concurrently" or "simultaneous," "sequential," or "separate" mean that the administration of the active agent and the vitamin D product are part of the same treatment regimen.
[0050] As defined herein, "simultaneous" administration includes administration of the active agent and vitamin D product within about 2 hours or within about 1 hour or less of each other, with administration at the same time being even more preferred.
[0051] As defined herein, "separate" administration includes administration of the active agent and vitamin D product more than about 12 hours, or more than about 8 hours, or more than about 6 hours, or more than about 4 hours, or more than about 2 hours apart.
[0052] As defined herein, "sequential" administration encompasses administration of each of the active agent and vitamin D product in multiple aliquots and / or multiple doses and / or on separate occasions. The active agent may be administered to the patient before or after administration of the vitamin D product. Alternatively, the vitamin D product continues to be administered to the patient after treatment with the active agent has ceased.
[0053] CD69 is a surface marker that becomes expressed as part of the cell's ability to interact with others. This is a sign that the cell is activated or is becoming activated. That is, CD69 expression increases in immune cells, such as CD3+ cells and T cells, when they are activated. Thus, in a second aspect, a method is provided for monitoring the treatment of a subject undergoing treatment with an active agent that is naltrexone or its metabolite or analogue, comprising: measuring CD69 expression in a CD3+ cell sample obtained from the subject undergoing treatment; and if said CD69 expression is increased compared to a control, said active agent is administered at an effective level.
[0054] The expression level of CD69 can be measured in a cell population using any number of analytical methods available to one of skill in the art, including, but not limited to, gel electrophoresis and Western blot analysis, 2D-PAGE, column chromatography, ribosome profiling, or mass spectrometry. All other embodiments described for the first aspect are applicable to the second aspect. EXAMPLES
[0055] Example 1: Cellular state determined by genes expressed and activated following administration of naltrexone and low-dose naltrexone CD3+ cells were harvested from CD14-ve peripheral blood mononuclear cells (PBMCs) cultured with 10 nM low-dose naltrexone (LDN) or 10 μM conventional high-dose naltrexone (NTX) for 4 hours. RNA was then extracted from the cells using Trizol and then isopropanol. Gene expression was measured using the Illumina platform and a whole human genome biochip. Nonsense genes and genes called as absent were filtered, leaving 19,571 genes called as present for further analysis. Treated:untreated ratios were calculated and a 25% change from untreated was considered relevant. The data were then sorted based on patterns. The effect of LDN or NTX could be either an increase, decrease, or no change in gene expression. Genes that were specifically altered by LDN may represent genes related to their function, for example, 223 genes were upregulated by LDN but not by NTX. Some of these genes are listed in Table 3, along with associated data showing that their expression is increased after LDN administration and that their expression is decreased or unchanged after NTX administration. Similarly, Table 3 lists some of the above genes, along with associated data showing that their expression is decreased after LDN administration and that their expression is unchanged after NTX administration.
[0056] [Table 3]
[0057] Example 2: CD3+ activation after LDN administration Peripheral blood mononuclear cells were isolated from whole blood obtained from pathologically healthy donors or from the residue of leucoreduction of whole blood using Histopaque-1077. The mononuclear fraction was collected and red blood cell contaminants were removed by incubation in hypotonic ammonium chloride solution. Cells were washed with phosphate-buffered saline (PBS), centrifuged at 200 g for 10 min to remove platelet contaminants, and cultured at 1 × 10 in RPMI-1640 medium. 6 The cells were resuspended at a concentration of 1000 ml. Naltrexone was added to the cells at either 10 μM conventional high-dose naltrexone (NTX) or 10 nM low-dose naltrexone (LDN) and incubated for 48 h at 37 °C in a humidified atmosphere containing 5% CO2 in air. Peripheral blood mononuclear cells were washed twice with washing buffer (PBS containing 1% (v / v) FBS and 0.09% (v / v) NaN3) and stained with relevant and indicated antibodies for 30 min at 4 °C for evaluation of immune cell profile. Cells were washed with washing buffer and fixed in 4% paraformaldehyde for 20 min at 4 °C. Surface marker expression was analyzed using a BD Science LSR II Flow Cytometer and proprietary software.
[0058] result The activation state of CD3+ cells is indicated by CD69 expression; higher expression levels of CD69 correlate with increased activation of CD3+. CD3+ cells are T cell coreceptors that help activate both cytotoxic T cells (CD8+ naive T cells) and helper T cells (CD4+ naive T cells). As shown in Figure 1, CD69 expression in CD3+ / CD8+ cells (killer T cells) increased after incubation with LDN, but not after incubation with NTX or solvent control (DMSO). Thus, once LDN priming is complete and gene expression is quantified in Example 1, the immune system is appropriately boosted.
Claims
1. 1. A method for monitoring treatment of a subject undergoing therapy with an active agent that is naltrexone or a metabolite or analog thereof, comprising: Measuring the gene expression profile of any of the genes listed in a) or b) below in a CD3+ cell sample obtained from the subject receiving the treatment: a) i. S100 calcium binding protein A6 (mRNA); ii. RAS protein activator like 3 (mRNA); iii. Mitogen-activated protein kinase kinase kinase kinase 1 (mRNA); iv. tyrosine 3-monooxygenase / tryptophan 5-monooxygenase (mRNA); v. DR1-related protein 1 (negative cofactor α2) (mRNA); vi. castor zinc finger 1, transcript variant 2 (mRNA); vii. Aldehyde dehydrogenase 4 family, member A1 (mRNA); viii. phenylalanine hydroxylase (mRNA); ix. myosin, light chain polypeptide kinase, transcript variant 5 (mRNA); x. Eukaryotic translation initiation factor 4B (mRNA); xi. Olfactory receptor, family 10, subfamily A, member 6 (mRNA); xii. Ezrin, transcript variant 1 (mRNA); xiii. actin, β (mRNA); xiv. PRP8 precursor RNA processing factor 8 (S. cerevisiae) homolog (mRNA); xv. integrin, β2 (complement component 3 receptors 3 and 4) (mRNA); xvi. hippocalcin-like 1, transcript variant 2 (mRNA); xvii. SPARC / osteonectin, cwcv and Kazal-like domain proteoglycan 2 (mRNA); xviii. poliovirus receptor-related 2 (herpesvirus entry mediator B) (mRNA); xix. nucleobindin 1 (mRNA); or b) i. WD repeat domain 75 (mRNA); ii. baculovirus IAP repeat-containing 3, transcript variant (mRNA); iii. CDKN2A interacting proteins (mRNA); iv. dynein, light chain, LC8-type 2 (mRNA); v. eukaryotic translation initiation factor 2, subunit 3 gamma (mRNA); vi. ArfGAP (mRNA) with SH3 domain, ankyrin repeats, and PH domain 1; vii. potassium channel tetramerization domain-containing 6 (mRNA); viii. Proteasome (prosome, macropein) activator subunit 2 (mRNA); ix. Mortality factor 4-like 1, transcript variant 2 (mRNA); x. metal-regulated transcription factor 1 (mRNA); xi. Peroxisomal D3, D2-enoyl-CoA isomerase, transcript (mRNA); xii. programmed cell death 4 (tumor transformation inhibitor) (mRNA); xiii. histone cluster 1, H4c (mRNA); xiv. BCL2-associated transcription factor 1, transcript variant (mRNA); xv. eukaryotic translation initiation factor 3, subunit E (mRNA); xvi. LSM5 (S. cerevisiae) homolog, U6 nuclear small RNA binding (mRNA); xvii. H3 histone, family 3A (mRNA); xviii. eukaryotic translation initiation factor 3, subunit M (mRNA); xix. CDC42 small molecule effector 2, transcript variant 2 (mRNA); The active agent is administered at an effective level if the expression of any of the genes in a) above is increased by at least 25% compared to a control, or if the expression of any of the genes listed in b) above is decreased by at least 25% compared to a control, the control is a sample obtained from the subject prior to treatment; the metabolite or analog is 6-β-naltrexol, naloxone, or methylnaltrexone; method.
2. The method of claim 1 , wherein gene expression profiles of three or more of said genes are determined.
3. 3. The method of claim 1 or 2, wherein the expression profile of one or more of the S100 calcium binding protein A6 gene (mRNA), RAS protein activator-like 3 gene (mRNA), mitogen-activated protein kinase kinase kinase kinase 1 gene (mRNA), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase gene (mRNA), and DR1-related protein 1 (negative cofactor alpha 2) gene (mRNA) is determined.
4. 4. The method of claim 3, wherein the expression profiles of each of the S100 calcium-binding protein A6 gene (mRNA), the RAS protein activator-like 3 gene (mRNA), the mitogen-activated protein kinase kinase kinase kinase 1 gene (mRNA), the tyrosine 3-monooxygenase / tryptophan 5-monooxygenase gene (mRNA), and the DR1-related protein 1 (negative cofactor alpha 2) gene (mRNA) are determined.
5. WD repeat domain 75 gene (mRNA), containing baculovirus IAP repeats 3. The method of any one of claims 1 to 4, wherein the expression profile of one or more of the following is determined: transcript variant gene (mRNA), CDKN2A interacting protein gene (mRNA), dynein, light chain, LC8-type 2 gene (mRNA), and eukaryotic translation initiation factor 2, subunit 3 gamma gene (mRNA).
6. 6. The method of claim 5, wherein the expression profiles of each of the WD repeat domain 75 gene (mRNA), the baculovirus IAP repeat-containing 3, transcript variant gene (mRNA), the CDKN2A-interacting protein gene (mRNA), the dynein, light chain, LC8-type 2 gene (mRNA), and the eukaryotic translation initiation factor 2, subunit 3 gamma gene (mRNA) are determined.
7. The method of any one of claims 1 to 6, wherein the active agent is naltrexone or 6-β-naltrexol.
8. The method of any one of claims 1 to 7, wherein the active agent is administered at a daily dose level of 4.5 mg or less.
9. 9. The method of claim 8, wherein the active agent is administered at a daily dose level of 3 to 4.5 mg.
10. The method of any one of claims 1 to 9, wherein the subject has cancer.
11. The method of claim 10, wherein the subject has breast cancer, lung cancer, melanoma, colon cancer, or glioma.
12. The method according to any one of claims 1 to 11, wherein the treatment is cancer treatment.
13. 13. The method of claim 12, wherein the cancer treatment is chemotherapy, radiation therapy, hormone therapy, or immunotherapy.
14. 14. The method of claim 13, wherein the cancer treatment is chemotherapy.
15. The method of any one of claims 1 to 9, wherein the treatment is an HIV / AIDS treatment.
16. 16. The method of claim 15, wherein the treatment is an antiretroviral therapy.
17. The method of any one of claims 1 to 16, wherein the gene expression profile is determined in a sample obtained at least 24 hours after treatment.
18. 18. The method of claim 17, wherein the sample is obtained at least 48 hours after the treatment.
19. The method of any one of claims 1 to 18, wherein the CD3+ cells are obtained from a blood sample of the subject.
Citation Information
Patent Citations
Treatment of cancer using naltrexone
JP2016524602A
An agent that increases the expression of the opioid kappa 1 for the treatment of cancer
WO2018178676A1
